# Pharmacokinetics in Subjects With Renal Impairment

> **NCT01504165** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** cilengitide 2000mg
- **DRUG:** cilengitide 2000mg
- **DRUG:** cilengitide 2000mg
- **DRUG:** cilengitide 1000mg
- **DRUG:** cilengitide > 1000mg and up to 2000mg

## Key facts

- **NCT ID:** NCT01504165
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01504165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01504165, "Pharmacokinetics in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01504165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*